No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
Evercore Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $46
Express News | Novocure Ltd - Appoints Ashley Cordova as CEO Effective Jan 1, 2025
NovoCure Shares Are Trading Higher After Piper Sandler Maintained an Overweight Rating on the Stock and Raised Its Price Target From $28 to $42.
Novocure Is Maintained at Overweight by Piper Sandler